Drugs to Extend Lifespan in COVID-19 Patients

In the Randomized REMAP-CAP Study published in the JAMA medical journal (JAMA. 2023;329(1):39-51) IL-6 receptor antagonists (tocilizumab, sarilumab, satralizumab, and siltuximab) and anti-platelet agents significantly increase the probability of long-term (six-month) survival of COVID-19 patients in poor general condition. found to increase. The same study showed that therapeutic anti-coagulation, convalescent plasma or lopinavir-ritonavir did not improve long-term survival, while hydroxychloroquine reduced the probability of survival. Corticosteroids did not have a significant effect on long-term survival. 

Source: jamanetwork.com/journals/jama/fullarticle/2799870